Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study for Continued Access to Napabucasin
jRCT2080225319Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of napabucasin in Non-hematologic malignancy, sponsored by Sumitomo Pharma. Started Aug 2020; status: completed.
02
Drugs
napabucasin
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080225319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225319.